1. This list refers to metal-b-lattamasa inhibitor compounds. The compound also refers to a compound composed of an existing metal-b-lactose inhibitor or a pharmaceutically acceptable salt, and an alternative pharmaceutically acceptable vehicle, plus a betalactic antibiotic and / or a b-lacthasa inhibitor. It also mentions ways to treat bacterial infections, including treating patients effectively, extracting an effective amount from current compounds,One or more antibiotics with one or more antibiotics can be selectively added with one or more acrylic acid inhibitors. 1. Claim 1: a formula compound (1),Or a pharmaceutically acceptable salt, wherein: X1 is n or CH； X2 is n or CH； Z is a tetrad, and Z is connected with the core of six X1 and X2 members through a carbon carbon link；RA es - (CH) -AryA- (CH) -HetA- (CH) -cicloalquilo C o (CH) -cicloalquenilo Cwherein said - (CH₂) ₙ -C₄₋₆ cycloalkyl and - (CH₂) ₙ-C₄₋₆ cycloalkenyl are optionally substituted with 1, 2 or 3 substituents independently selected from -NH₂,-OH, -F and -NRᵃC (O) C₁₋₆ alkyl optionally substituted with 1 or 2 substituents independently selected from -F, -CF₃,-No. 7491； r7495y-or74919；R es 1) -NH2) - alternative No. 749191-c83231-832626, replaced by alternative No. 1, 2, 3 or 4 independently selected from: - F, - cf8323；1. Lease land No. c833218331 and 832626；-CH (NH) C (O) NH-C (o) No. 7491； (r7495)；-C (O) OH - (CH) NH-NRᵃ (CH₂) ₂₋₃NH₂,-No. 7491； No. 74955；-N R R CH-NHCH₂CH₂OCH₃,-OR y -O (CH) NH3) -NRᵃC (O) C₁₋₆ alkyl optionally substituted with 1 or 2 substituents independently selected from: -F, -CF₃,-C (o) No. 7491； (r7495)；-C (o) - No. 7491； r74955；-N R R CH-NHCH₂CH₂OCH₃,-OR y -O (CH) NH4) -NR (CH) -cicloalquilo Cwherein the C₃₋₆ cycloalkyl is optionally substituted with -CH₂OH or -NH₂；(5) A single ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring double ring
